Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 9 clinical trials
A Study Evaluating The Safety Tolerability Pharmacokinetics And Efficacy Of Venetoclax In Combination With Atezolizumab Carboplatin And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

A study consisting of a dose-escalation phase and a dose-expansion phase to evaluate the safety, tolerability, pharmacokinetics, and efficacy of venetoclax in combination with atezolizumab, carboplatin, and etoposide.

cns metastases
measurable disease
colony stimulating factor
chemotherapy regimen
cancer treatment
  • 0 views
  • 19 Feb, 2024
  • 16 locations
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine Cyclophosphamide and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or bendamustine + rituximab (FCR/BR) in FIT participants (FIT is defined by a cumulative illness rating scale [CIRS]/score of 6 and a normal creatinine clearance of 70 mL/min) …

blood transfusion
17p deletion
rituximab
myelodysplastic syndrome
lymphoid leukemia
  • 0 views
  • 19 Feb, 2024
  • 51 locations
Venetoclax SL-401 and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

This phase II trial studies how well venetoclax, SL-401, and chemotherapy works in treating patients with blastic plasmacytoid dendritic cell neoplasm. Venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

gilbert's syndrome
ejection fraction
hydroxyurea
treatment regimen
cytarabine
  • 0 views
  • 19 Feb, 2024
  • 1 location
Healthy Test study

This is a multi center two-stage, two-arm, open label phase II study of venetoclax in combination with azacytidine in acute myeloid leukemia patients selected for therapy with ex vivo venetoclax

  • 0 views
  • 19 Feb, 2024
  • 1 location
Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening

This is a multi center two-stage, two-arm, open label phase II study of venetoclax in combination with azacytidine in acute myeloid leukemia patients selected for therapy with ex vivo venetoclax sensitivity screening.

graft versus host disease
ejection fraction
hydroxyurea
heart failure
allogeneic transplantation
  • 0 views
  • 19 Feb, 2024
  • 1 location
Ibrutinib + Venetoclax in Untreated WM

The names of the study drugs involved in this study are: Venetoclax ibrutinib

waldenstrom's macroglobulinemia
venetoclax
bone marrow biopsy
absolute neutrophil count
measurable disease
  • 0 views
  • 19 Feb, 2024
  • 2 locations
Azacitidine Venetoclax and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax and trametinib may stop the growth of cancer cells by blocking some of the enzymes needed for …

serum bilirubin
BRAF
recurrent acute myeloid leukemia
myelodysplastic syndrome
recurrent myelodysplastic syndrome
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

The purpose of this study is to evaluate the safety and efficacy (how well the study drug works against the disease) of Venetoclax in combination with Pembrolizumab in participants with NSCLC. Venetoclax is a drug that kills cancer cells by blocking a protein (part of a cell) that allows cancer …

erbb1
egf receptors
measurable disease
solid tumor
epidermal growth factor receptor
  • 0 views
  • 19 Feb, 2024
  • 39 locations
A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian Federation

Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well Venetoclax works to treat AML in adult participants who are ineligible for standard induction therapy in Russian Federation. Venetoclax is a drug …

  • 0 views
  • 19 Feb, 2024
  • 3 locations